Engflag

Tice

Quick links to important sections

Tice

Tice_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tice

Property Description
Active Ingredient Bacillus Calmette-Guérin (BCG)
Form Lyophilized powder for reconstitution
Pharmacological Class Immunomodulator, Biological Response Modifier
General Purpose To stimulate a localized immune response
Origin Live, attenuated culture of Mycobacterium bovis

Tice is a highly specialized biologic agent classified as a biological response modifier and immunomodulator. It is a prescription-only medicine that works primarily by engaging and modulating the body's natural defense systems. Tice is derived from the Bacillus Calmette-Guérin (BCG) organism, an attenuated, or weakened, strain of Mycobacterium bovis.

This unique origin and subsequent therapeutic application situate Tice within the high-level pharmacological class of antineoplastic agents, as its function involves leveraging the innate power of immunotherapy to manage specific types of abnormal cellular growth. The regulatory overview confirms that this drug is approved to help the body's own defenses target unwanted cells.

The active ingredient in Tice is the live, attenuated strain of Mycobacterium bovis, which is strictly prepared as a lyophilized powder for reconstitution. This formulation requires aseptic mixing with a sterile liquid before administration, resulting in a suspension for intravesical use (into the bladder). The general purpose of Tice is to stimulate the patient's immune system to recognize and control abnormal cells, functioning as a localized form of immunotherapy. The introduction of the attenuated bacteria triggers a strong, localized immune response, which involves the attraction and activation of defense cells, such as T-cells, within the targeted area, aiding the body's defenses in controlling the proliferation of unwanted cell populations.

What side effects are possible with Tice?

The safety profile of Tice, an intravesical immunomodulator, is organized by regulatory bodies into adverse reactions categorized by frequency and the body system affected.

Adverse Reaction Scope

Category Description
Key Adverse Reactions Localized inflammatory reactions in the urinary system and systemic, transient flu-like symptoms (fever, malaise, chills).
Frequency Classification Very Common (ge 10%): Dysuria (painful urination), increased urinary urgency/frequency, hematuria, fever, and drug-induced cystitis. Common (1% to <10%): Urinary tract infection, anemia, abdominal pain, nausea, vomiting, myalgia, arthralgia, and arthritis. Very Rare (<0.01%): Includes acute renal failure and prostatitis.
System-Organ Classes The most affected systems are Renal and Urinary Disorders and General Disorders (systemic symptoms). Other systems include Musculoskeletal (joint/muscle pain) and Infections (risk of tuberculosis infection).
Serious Adverse Reactions The regulatory label documents the potential for serious, potentially fatal reactions, including Disseminated BCG Infection (BCGitis), Sepsis, Pneumonitis, and Orchitis.

Safety-Related Restrictions and Considerations

Category Description
Time-Related Patterns Expected local and systemic flu-like symptoms typically appear within 24 to 48 hours after treatment. Systemic BCG infection may have a delayed onset, developing months or years after therapy.
Restrictions Treatment must be postponed if the patient has a concurrent febrile illness, active urinary tract infection, or gross hematuria. A period of 7 to 14 days must elapse after procedures like a transurethral resection (TUR) or traumatic catheterization before administration.
Population Notes Immunosuppressed patients should not use the medication due to the risk of infection. Official documents note that elderly patients may have a potential increased risk of severe systemic BCG-infections.

The official safety information structures the risk profile by establishing that common and expected reactions are primarily localized and transient, reflecting the drug's mechanism as a localized immune stimulant. Simultaneously, the framework highlights the rare but critical risk of systemic infection, necessitating specific safety constraints regarding patient status and recent procedures before administration can proceed.

Overdose and Emergency Response

The regulatory guidance for Tice (intravesical BCG) addresses overdose not by acute toxicity from excess quantity, but through the severe, life-threatening risk of Systemic BCG Infection or Sepsis. This complication arises if the live, attenuated bacterium gains access to the systemic circulation, often following trauma to the bladder lining, and is considered a medical emergency.

When to Seek Immediate Medical Help

Immediate medical attention is required if signs of systemic dissemination are suspected, as this may lead to fatal outcomes or septic shock. These officially documented manifestations include febrile episodes or flu-like symptoms that persist for more than 72 hours, or a sustained fever of 103 F (39.4 C) or higher. Localized symptoms, such as prostatitis or orchitis, persisting for longer than two to three days also necessitate urgent evaluation.

Official Emergency Response

The emergency response requires the permanent discontinuation of Tice. Consultation with an infectious disease specialist is mandated to begin long-term, multi-drug anti-tuberculous therapy (e.g., Isoniazid, Rifampicin) immediately. The risk of this serious complication is heightened if the drug is administered following recent bladder trauma, such as a biopsy, or in immunosuppressed patients, for whom the drug is officially contraindicated.

Therapeutic Uses of Tice

Tice is a medication specifically used for managing certain forms of non-muscle invasive bladder cancer (NMIBC). It is primarily administered to address abnormal cell growth and tumors that remain on the lining of the bladder. The medication is used for patients with high-risk disease features, including Carcinoma in Situ (CIS), a condition characterized by high-grade abnormal cells on the inner lining.

The medication is commonly used following a transurethral resection (TUR) procedure. The primary benefit in this context is to help reduce the probability of the tumor recurring in individuals with these specific high-risk features. This is a crucial element of the long-term management strategy for NMIBC. The treatment aims to assist in the overall management plan tailored by the healthcare team, with the overarching goal of promoting long-term stability in the condition.

Quick Fact: Management of Recurrence Risk Tice is used as an established option to reduce the probability of recurrence in patients with high-risk, non-muscle invasive bladder cancer.

Eligibility and Restrictions for Use

Official Population Eligibility for Tice (BCG)

The criteria for using Tice are strictly defined by regulatory bodies, focusing on the patient's existing health status and specific clinical conditions, as the medicine is a live biological agent.

Absolute Non-Eligibility (Contraindications)

Category Regulatory Status
Immune Status Contraindicated in patients with congenital or acquired immunosuppression or those receiving immunosuppressive therapy.
Infection Status Contraindicated with active tuberculosis, febrile illness, or a symptomatic urinary tract infection (UTI).
Reproductive Status Contraindicated during pregnancy and not recommended during lactation.
Hypersensitivity Contraindicated with known hypersensitivity to the active substance.

Conditional Use and Age Restrictions

Administration must be postponed for seven to fourteen days following procedures such as a transurethral resection (TUR), bladder biopsy, or in the presence of gross hematuria. Use is established and approved in the adult population (aged ge 18); however, safety and efficacy have not been established in pediatric patients.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation confirms that the interaction profile for Tice (Bacillus Calmette-Guérin) is based on pharmacodynamic constraints related to its function as a live, attenuated biological response modifier.

Documented Interaction Restrictions

Category Regulatory Status & Statement
Immunosuppressive Agents Prohibited Co-administration: Use with immunosuppressive drugs, bone marrow depressants, or radiation is prohibited due to the risk of additive immunosuppressive effects and subsequent infection from the live BCG organism.
Antituberculosis Agents Prohibited Co-administration: Combination with antituberculosis drugs, including Isoniazid (INH), Rifampicin, Ethambutol, and para-aminosalicylic acid (PAS), is strictly prohibited due to the potential for loss of Tice's intended anti-tumour activity.
Antimicrobial Agents Timing Separation Required: Tice instillation must be postponed or interrupted until any co-existing urinary tract infection is resolved and the therapy with antibiotics or urinary antiseptics is completely stopped.

These restrictions are mandated to preserve the viability of the live organism and the integrity of the localized immune response it is intended to stimulate. No standard pharmacokinetic interactions (e.g., CYP enzyme effects) are documented in the official prescribing information.

Mechanism of Action

Tice, a preparation of the attenuated live culture Bacillus Calmette-Guérin (BCG) strain of Mycobacterium bovis, is administered directly into the bladder, establishing a localized infection. This bacterial presence acts as a biological response modifier by triggering a potent local immune response.

The bacterial components, recognized as foreign antigens, engage with urothelial cells and immune cells present in the bladder wall, including macrophages and dendritic cells.

This interaction initiates the activation and recruitment of various immune subsets, such as T lymphocytes and natural killer (NK) cells. The ensuing intracellular pathway involves the secretion of various cytokines and chemokines, including interleukins (e.g., IL-2, IL-6, IL-12) and interferon-gamma (IFN-gamma). This cascade of signaling molecules induces a profound granulomatous inflammatory reaction at the site of administration. The system-level physiological consequence of this localized immunomodulation is the establishment of a robust, non-specific cytotoxic environment, mediating damage to abnormal cells in the superficial layers of the bladder.

Dosage and Administration Information

Official Administration Guidelines for Tice Intravesical Suspension

Tice (Bacillus Calmette-Guérin [BCG] Live) is administered by intravesical instillation directly into the bladder via a catheter. It must not be injected intravenously or subcutaneously.

Dosing and Preparation

The standard adult dose is one vial of TICE BCG, which is reconstituted and then suspended in 50 mL of sterile, preservative-free saline.

  • Reconstitution: Add 1 mL of sterile, preservative-free saline to one vial and gently swirl to obtain a homogeneous suspension. Avoid forceful agitation.
  • Dilution: Dilute the suspension in sterile, preservative-free saline to the final 50 mL volume.
  • Timing: The final suspension must be used within two hours of preparation.

Treatment Schedule and Procedure

  1. Delay Instillation: Treatment should be postponed until 7 to 14 days have passed after a bladder biopsy, transurethral resection (TUR), or traumatic catheterization.
  2. Fluid Restriction: Patients should not drink fluids for four hours before the procedure and must empty their bladder completely prior to instillation.
  3. Instillation: The 50 mL suspension is instilled into the bladder by gravity flow via a catheter.
  4. Retention: The agent should be retained in the bladder for two hours.
  5. Repositioning: To maximize bladder surface exposure, the patient should ideally be repositioned every 15 minutes (left side, right side, back, abdomen) during the two-hour retention period.
  6. Voiding: After the retention time, the patient must void the suspension.

Frequency Pattern

  • Induction: Once weekly for six consecutive weeks.
  • Maintenance: Should continue at approximately monthly intervals for a period of at least six to twelve months thereafter. The induction schedule may be repeated once if remission has not been achieved.

Recent Clinical Evidence

Tice, a specific strain of Bacillus Calmette-Guérin (BCG), is used as an intravesical immunotherapy primarily for non-muscle-invasive bladder cancer (NMIBC). Clinical evidence has established its role in the treatment and prophylaxis of carcinoma in situ (CIS) and the prevention of recurrence for Stage Ta and/or T1 papillary tumors following transurethral resection (TUR).

Efficacy in Disease-Free Survival

Clinical trials, including studies conducted by the Southwestern Oncology Group (SWOG), have evaluated the effectiveness of Tice BCG compared to chemotherapy agents like Mitomycin C (MMC) in high-risk patients. One key study reported an estimated 2-year disease-free survival (DFS) rate of approximately 57% for the Tice BCG arm, compared to 45% for the MMC arm. This difference in DFS was found to be statistically significant, supporting the use of BCG immunotherapy in this setting.

Comparative and Long-Term Data

  • Strain Comparisons: Studies comparing Tice to other BCG strains, such as RIVM or Connaught, often show similar overall progression-free survival (PFS) rates. However, one sub-analysis observed Tice to be associated with a longer time to recurrence in a specific patient subgroup that received maintenance therapy after secondary resection.
  • Duration of Response: For patients who achieve a complete response (CR), the median duration of response (time to recurrence) has been estimated at four years or greater in historical data.
  • Combination Therapies: Recent research is exploring the use of Tice BCG in combination with other agents, such as electromotive Mitomycin C, which has been investigated for potential improvements in remission rates and longer disease-free intervals compared to BCG alone.

Frequently Asked Questions (FAQ)

Common questions about Tice (FAQ)

Q: Is Tice the same as the BCG vaccine used for tuberculosis?

A: Tice contains Bacillus Calmette-Guérin (BCG) Live, which is an attenuated (weakened) strain of Mycobacterium bovis. Official regulatory documents confirm that this same organism is also utilized in a vaccine intended to provide protection against tuberculosis (TB). When Tice is used for bladder conditions, it is administered locally into the bladder, not as a standard systemic vaccine.

Q: Is Tice treatment known to cause long-term side effects?

A: The regulatory label documents the possibility that rare but serious complications, specifically disseminated BCG infection (BCGitis), may not develop until months or even years after therapy. This is related to the organism potentially persisting in the urinary tract. Information regarding the frequency and nature of other specific long-term effects beyond disseminated infection is not generally specified in the standard adverse reaction tables.

Q: Can Tice treatment affect the results of a tuberculosis (TB) skin test?

A: Yes, regulatory guidances for BCG products state that the treatment may cause a false-positive reaction to the Tuberculin Skin Test (TST). This happens because the Tice organism can increase tuberculin sensitivity. The Interferon-Gamma Release Assay (IGRA) blood test is one alternative diagnostic tool that may be considered for evaluating tuberculosis exposure in patients who have received BCG.

Q: Are flu-like symptoms a sign that Tice is working?

A: Flu-like symptoms, such as fever, malaise, and chills, are classified as Very Common and expected side effects of Tice. The symptoms are consistent with the drug's classification as a biological response modifier, which functions by stimulating the immune system. They are common reactions, not a formal measure of therapeutic success.

Q: Does Tice have a warning related to patients with a small bladder capacity?

A: Yes, official regulatory documents note that the risk of bladder contracture (shrinking of the bladder) may increase in patients who have a low bladder capacity. Official documentation advises caution for its use in patients with this pre-existing condition.

Q: Are there different brands or names for the BCG drug, like Tice and TheraCys?

A: Yes. The active ingredient, Bacillus Calmette-Guérin (BCG) Live, is manufactured and sold under several brand names, including Tice and TheraCys. These represent different substrains or preparations of the BCG organism.

Q: What is the purpose of the 'maintenance' phase of Tice treatment?

A: Tice is indicated for the prophylaxis (prevention) of recurrence of certain types of bladder tumors. The maintenance phase is established in the product schedule to prolong the immune response and support the sustained prevention of tumor recurrence.

Q: What is the difference between Tice and other treatments for similar conditions?

A: Tice is classified as a biological response modifier and is a type of immunotherapy. Unlike traditional chemotherapy drugs, which use chemicals to destroy cells, Tice uses a live, attenuated (weakened) bacterium to leverage the body’s local immune system to help control abnormal cell growth. Studies often compare Tice to agents like Mitomycin C (a chemotherapy drug) to assess their different roles in managing the condition.

Q: What are the signs of a more serious, rare infection related to Tice?

A: Regulatory warnings highlight the potential for serious reactions, including Disseminated BCG Infection (BCGitis) and Sepsis. Patients experiencing persistent fever, chills, new respiratory symptoms, or pain outside the urinary tract should be assessed, as these manifestations can be associated with systemic infection.

Q: Are there any food or drink restrictions while undergoing Tice treatment?

A: Official administration guidelines state that patients should not drink fluids for four hours before the procedure to ensure the bladder is empty. This restriction applies specifically to fluids prior to treatment. The regulatory label does not generally define specific restrictions on food or other drinks outside of this particular preparation instruction.

Q: Why is it important to hold the Tice solution in the bladder for a specific time?

A: Official administration guidelines specify that the solution must be retained in the bladder for two hours. This retention time is necessary to maximize bladder surface exposure to the medication. The retention is designed to allow the live bacterium sufficient contact time with the bladder wall to engage the localized immune response described in the drug's mechanism of action.

Q: What does 'intravesical therapy' mean in relation to Tice?

A: Intravesical therapy refers to a method of administration where a drug is delivered directly into the bladder via a catheter. This delivery method is chosen for Tice because it allows the medication to work locally at the site of the condition. The official name for the process is intravesical instillation.

Q: What happens if Tice enters the bloodstream?

A: The official product information states that Tice must not be injected intravenously (into the vein) or subcutaneously (under the skin). Systemic entry of the live BCG organism into the circulation is associated with a risk of serious complications, including Disseminated BCG Infection (BCGitis) and Sepsis.

Q: Why is Tice sometimes postponed after a biopsy or traumatic catheterization?

A: The treatment must be postponed for seven to fourteen days after procedures such as a transurethral resection (TUR), bladder biopsy, or any traumatic catheterization. The postponement is a required safety measure, as administration when the bladder lining is injured is associated with a potential increase in the systemic absorption of the live organism.

Q: Can Tice make me more susceptible to other infections?

A: Official safety information notes the serious risk of a BCG infection and the requirement to resolve any pre-existing urinary tract infection (UTI) before treatment. However, the regulatory label does not generally state that the treatment's immunomodulating effect makes patients more susceptible to common, unrelated external infections like the cold or flu.

How should Tice be stored and disposed of?

The Tice (BCG) powder is a live, attenuated bacterial preparation and must be stored and handled with care to maintain potency and prevent the risk of infection. The unopened vials should be kept refrigerated at a temperature between 2°C and 8°C (36°F and 46°F) and protected from light.

Once reconstituted with sterile, preservative-free saline, the suspension must be used within two hours and kept refrigerated. Any unused portion of the reconstituted drug must be discarded.

Due to its biohazardous nature, all equipment, supplies, and receptacles that have come into contact with Tice, including the catheter and voided urine for the first six hours after administration, must be handled and disposed of as biohazard material following institutional guidelines. For home disposal of urine during the initial six-hour period, a disinfectant, such as household bleach, must be added to the toilet bowl and allowed to stand for 15 minutes before flushing.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Tice found in:

A-Z Index: